Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald P Cameron

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Molecular Cell|December 10, 2021
MYC assembles and stimulates topoisomerases 1 and 2 in a "topoisome"Subhendu K Das, Vladislav Kuzin, Donald P Cameron, et al.
Communications Biology|February 1, 2019
Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformationJeannine Diesch, Megan J Bywater, Elaine Sanij, et al.
Genome Research|December 3, 2014
A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genesElaine Sanij, Jeannine Diesch, Analia Lesmana, et al.
International Journal of Cancer|December 16, 2017
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistanceClaire A Martin, Carleen Cullinane, Laura Kirby, et al.
Cancer Discovery|May 17, 2019
First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation StudyAmit Khot, Natalie Brajanovski, Donald P Cameron, et al.
Cancer Research Communications|March 6, 2023
MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent MannerAlina Castell, Qinzi Yan, Karin Fawkner, et al.
Pigment Cell & Melanoma Research|February 6, 2014
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell linesRichard J Young, Kelly Waldeck, Claire Martin, et al.
Oncotarget|July 9, 2016
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingJaclyn Quin, Keefe T Chan, Jennifer R Devlin, et al.
Science Advances|October 13, 2023
Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcriptionDonald P Cameron, Jan Grosser, Swetlana Ladigan, et al.
Blood|March 12, 2017
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationNadine Hein, Donald P Cameron, Katherine M Hannan, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Molecular Cell|December 10, 2021
MYC assembles and stimulates topoisomerases 1 and 2 in a "topoisome"Subhendu K Das, Vladislav Kuzin, Donald P Cameron, et al.
Communications Biology|February 1, 2019
Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformationJeannine Diesch, Megan J Bywater, Elaine Sanij, et al.
Genome Research|December 3, 2014
A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genesElaine Sanij, Jeannine Diesch, Analia Lesmana, et al.
International Journal of Cancer|December 16, 2017
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistanceClaire A Martin, Carleen Cullinane, Laura Kirby, et al.
Cancer Discovery|May 17, 2019
First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation StudyAmit Khot, Natalie Brajanovski, Donald P Cameron, et al.
Cancer Research Communications|March 6, 2023
MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent MannerAlina Castell, Qinzi Yan, Karin Fawkner, et al.
Pigment Cell & Melanoma Research|February 6, 2014
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell linesRichard J Young, Kelly Waldeck, Claire Martin, et al.
Oncotarget|July 9, 2016
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingJaclyn Quin, Keefe T Chan, Jennifer R Devlin, et al.
Science Advances|October 13, 2023
Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcriptionDonald P Cameron, Jan Grosser, Swetlana Ladigan, et al.
Blood|March 12, 2017
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationNadine Hein, Donald P Cameron, Katherine M Hannan, et al.
Pageof 2